“Raman analysis of saliva from COPD patients as new biomarker: AI-based point-of-care for the disease monitoring and management”
EraPerMed – Joint Transnational Call 2021
Duration: 42 months (01/02/2022 – 31/07/2025)
EraPerMed – Joint Transnational Call 2021
Duration: 42 months (01/02/2022 – 31/07/2025)
COPD is a leading cause of morbidity and mortality worldwide. Current diagnostic and monitoring tools are often invasive, time-consuming, or poorly sensitive to early molecular changes. Saliva is an ideal candidate for non-invasive sampling, and Raman spectroscopy allows rapid molecular-level analysis with high specificity.
The integration of AI algorithms with RS data and clinical information represents a disruptive innovation in the COPD care pathway. CORSAI aims to fill the gap between molecular diagnostics and personalised care, offering clinicians new tools for precision medicine in respiratory disease.
The main goal of the CORSAI project is to create and validate a novel, non-invasive diagnostic method based on Raman spectroscopy (RS) analysis of saliva, aimed at improving the personalised management of patients with Chronic Obstructive Pulmonary Disease (COPD).
By combining clinical instrumental data with RS-based molecular profiling and Artificial Intelligence (AI), CORSAI will support clinicians in:
This integrated approach will provide an objective, AI-driven decision-support system for point-of-care application, ultimately enhancing the quality of clinical COPD care.
CORSAI is a European project funded under the EraPerMed – Joint Transnational Call 2021, coordinated by Fondazione Don Gnocchi – Milan, Italy (Dr. Banfi and Dr. Bedoni).
Project partners include:
The CORSAI project successfully recruited 74% of the planned subjects. The main achievements included the development of an AI-based classification model capable of distinguishing between all subject groups, integrated into the Blue Cherry software, which interpolates clinical and Raman spectroscopy data. Moreover, the use of portable Raman spectroscopy allowed us to test the real potential for translating this system into clinical practice with high accuracy. A particularly impactful result was the ability to assess the contribution of pharmacological treatment to the salivary signature, providing a novel approach to monitoring patient adherence to therapy and personalizing treatments.